WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data

Vestibular Schwannoma Clinical Trial

— NF2  

Official title:

Whole Exome Sequencing (WES) of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03210285
• Other study ID #: NF2Tue
• Status: Completed
• Start date: July 31, 2017
• Est. completion date: July 1, 2018

Study information

• Verified date: July 2017
• Source: University Hospital Tuebingen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults. The aim is to gain insight into the complete genome of the NF2 associated VS compared to sporadic VS (control group). These data are to be correlated with the clinic, ie the auditory function (audiogram, acoustically evoked potentials) and the clinical picture as well as the tumor growth rate and general data such as sex, age, side, etc.

Description:

Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults. The aim is to gain insight into the complete genome of the NF2 associated VS compared to sporadic VS (control group). These data are to be correlated with the clinic, ie the auditory function (audiogram, acoustically evoked potentials) and the clinical picture as well as the tumor growth rate and general data such as sex, age, side, etc.

The analysis of genetic changes should provide a better insight into the oncogenesis of these tumors. The distinct genetic characteristics between NF2-associated and sporadic VS suggest a different oncogenesis of these tumors.

The correlation of the genetic characteristics with the partly very different clinical appearance and a very different dynamics of the disease, in particular the tumor volume in the course, identifies the underlying modifiers of the disease course.

Based on these genetic modifiers, patients can be stratified and individual clinical therapy decisions can be made.

By demonstrating these genetic profiles in the peripheral blood, prospective conclusions can be drawn about expected disease progression before intervention as well as for therapy monitoring

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: July 1, 2018
• Est. primary completion date: April 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 99 Years

Eligibility

Inclusion Criteria:

• Study population: Operated NF2-associated VS

• Control group: Operated sporadic VS

• Consent to participation in the study by the patient / legal guardian in prospective inclusion or consent to the use of stored specimens in retrospective inclusion

• Age: 0 -99 years

Exclusion Criteria:

• Lack of informed consent

• Patient's request (withdrawal of the consent statement for the evaluation of the data and further storage of the blood / tissue samples)

Related Conditions & MeSH terms

• Acoustic Neuroma
• Neurilemmoma
• Neurofibroma
• Neurofibromatoses
• Neurofibromatosis 1
• Neurofibromatosis 2
• Neurofibromatosis Type 2
• Neuroma
• Neuroma, Acoustic
• Vestibular Schwannoma

Intervention

Diagnostic Test:
• Whole exome sequencing
Whole exome sequencing

Locations

Country	Name	City	State
Germany	University Department of Neurosurgery Tübingen	Tübingen

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Tuebingen	National Center for Tumor Diseases, Heidelberg

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation clinical-volumetric pathologies and distinct genetic features	Correlation between interindividually different clinical-volumetric pathologies and distinct genetic features	Within 1 week after measurement
Secondary	Identification of genetic profiles for pre-interventional prediction of expected disease progression	Identification of genetic profiles in the peripheral blood for pre-interventional prediction of expected disease progression as well as therapy monitoring	Within 1 week after measurement